Daiichi Sankyo showcases progress in developing new standards of care for patients with industry-leading DXd ADC portfolio across multiple cancers at ESMO

Daiichi Sankyo will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in multiple types of cancer at the 2023 European Society for Medical Oncology (ESMO23) Congress to be held 20-24 Oct 2023. Three late-breaking abstracts, including two Presidential Symposia presentations, are among the more than 20 abstracts showcasing Daiichi Sankyo's leadership and progress in developing new standards of care for patients with cancer. Data at ESMO will highlight results from the TROPION-Breast01 and TROPION-Lung01 phase 3 trials (LBA11 and LBA12) evaluating datopotamab deruxtecan (Dato-DXd) versus chemotherapy in patients with HR positive, HER2 low or negative metastatic breast cancer and advanced non-small cell lung cancer (NSCLC) during back-toback presentations at the Presidential Symposium 3. These data will be featured in an ESMO press briefing. Other late-breaking data includes a mini-oral session featuring the first presentation of progression-free and overall survival results from the DESTINY-PanTumor02 phase 2 trial (LBA34) evaluating ENHERTU (trastuzumab deruxtecan) across multiple HER2 expressing solid tumours, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic and other cancers. Updates from other trials across Daiichi Sankyo's DXd ADC portfolio include mini-oral sessions presenting an exploratory analysis of the intracranial efficacy of patritumab deruxtecan (HER3-DXd) in patients with EGFRmutated metastatic NSCLC from the HERTHENA-Lung01 phase 2 trial, and updated data from an ongoing first-inhuman phase 1 trial of raludotatug deruxtecan (R-DXd) in patients with previously treated ovarian cancer. A poster presentation also will feature updated clinical and biomarker results of ifinatamab deruxtecan (I-DXd) in patients with advanced solid tumours from an ongoing phase 1/2 trial. Additional datopotamab deruxtecan data at ESMO includes the first presentation from the TROPION-Lung05 phase 2 trial in patients with previously treated NSCLC with actionable genomic alterations and updated data from the BEGONIA phase 1b/2 trial in patients with previously untreated advanced/metastatic triple negative breast cancer during two mini-oral sessions. Other ENHERTU data to be highlighted in proffered paper or mini-oral sessions include the primary results from the DESTINY-PanTumor01 phase 2 trial in patients with solid tumours with HER2 activating mutations and a pooled analysis from the DESTINY-Lung01 and DESTINY-Lung02 phase 2 trials in patients with HER2 mutant metastatic NSCLC with and without brain metastases. A proffered paper session also will include updated survival results from the DESTINY-Breast04 phase 3 trial in patients with HER2 low metastatic breast cancer as well as pooled exploratory efficacy and safety analysis from the DESTINY-Breast01, DESTINY-Breast02 and DESTINYBreast03 trials in patients with HER2 positive metastatic breast cancer with brain metastases. Original source: Daiichi Sankyo Co Ltd, website: http://www.daiichisankyo.com/, Copyright Daiichi Sankyo Company Limited 2023.
research and development; anticancer drugs; datopotamab deruxtecan; ENHERTU; ifinatamab deruxtecan; monoclonal antibodies; therapeutic antibodies; trastuzumab deruxtecan; Daiichi [...]